MedTrace Logo

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

NCT04519151 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-06-08

No results posted yet for this study

Summary

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will receive pembrolizumab and lenvatinib.

Conditions

  • Ovarian Neoplasms
  • Carcinoma, Ovarian Epithelial
  • Neoplasm of Stomach
  • Ovarian Diseases
  • Genital Neoplasms, Female
  • Ovarian Epithelial Tumor
  • Urogenital Neoplasms
  • Neoplasms, Glandular and Epithelial

Interventions

DRUG

Pembrolizumab

200 mg administered by IV infusion on Day 1 of each 21-day cycle.

DRUG

Lenvatinib

20 mg administered orally (PO) QD during each 21-day cycle.

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-12
Primary Completion
2023-11-30
Completion
2029-11-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04519151 on ClinicalTrials.gov